Drug Trial Radar · NCT06745271
A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Mar 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Dec 20, 2024
Primary completion
Feb 21, 2025
Study completion Feb 21, 2025
Sponsor
- Lead sponsor
- Agios Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to determine the routes, rates of elimination, mass balance of total radioactivity and metabolite profiles following a single oral dose of \[14C\]-tebapivat. To characterize the PK of tebapivat and \[13C2,15N3\]-tebapivat and determine the absolute bioavailability following single oral dose of \[14C\]-tebapivat relative to single intravenous microdose of \[13C2,15N3\]-tebapivat to healthy male participants.
Conditions
- Healthy Participants
Interventions
[14C]-tebapivatDrug
Oral Capsule
[13C2,15N3]-tebapivatDrug
Intravenous Solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Radioactive Dose Excreted in Urine Over a Time Interval (feut1-t2) of [14C]-TebapivatTime frame: Up to Day 42
- Percentage of Radioactive Dose Excreted in Feces Over a Time Interval (fef t1-t2) of [14C]-TebapivatTime frame: Up to Day 42
- Cumulative Percentage of Radioactive Dose Excreted in Urine Over a Time Interval (Cum feut1-t2) of [14C]-TebapivatTime frame: Up to Day 42
- Cumulative Percentage of Radioactive Dose Excreted in Feces Over a Time Interval (Cum fef t1-t2) of [14C]-TebapivatTime frame: Up to Day 42
- Percentage of Total Radioactivity in Total Excreta (Feces + Urine) (Cum fe) of [14C]-TebapivatTime frame: Up to Day 42
- Amount of Drug Excreted in Urine (Aeu) of [14C]-TebapivatTime frame: Up to Day 42
- Cumulative Amount of Drug Excreted in Urine (Cum Aeu) of [14C]-TebapivatTime frame: Up to Day 42
- Renal Clearance (CLR) of [14C]-TebapivatTime frame: Up to Day 42
- Area Under the Concentration-Time Curve (AUC) From Time 0 to 168 Hours Postdose (AUC0-168) in Plasma for [14C]-Tebapivat and [13C2,15N3]-TebapivatTime frame: Up to Day 7
- AUC0-168 in Plasma and Whole Blood for Total RadioactivityTime frame: Up to Day 7
- AUC From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t) in Plasma for [14C]-Tebapivat and [13C2,15N3]-TebapivatTime frame: Up to Day 21
- AUC0-t in Plasma and Whole Blood for Total RadioactivityTime frame: Up to Day 42
- AUC Extrapolated to Infinity (AUC0-inf) in Plasma for [14C]-Tebapivat and [13C2,15N3]-TebapivatTime frame: Up to Day 21
- (AUC0-inf) in Plasma and Whole Blood for Total RadioactivityTime frame: Up to Day 42
- Maximum Observed Plasma Concentration (Cmax) for [14C]-Tebapivat and [13C2,15N3]-TebapivatTime frame: Up to Day 21
- Cmax in Plasma and Whole Blood for Total RadioactivityTime frame: Up to Day 42
- Time to Reach Cmax (Tmax) for [14C]-Tebapivat and [13C2,15N3]-TebapivatTime frame: Up to Day 21
- Tmax in Plasma and Whole Blood for Total RadioactivityTime frame: Up to Day 42
- Terminal Elimination Half-Life (t1/2) in Plasma for [14C]-Tebapivat and [13C2,15N3]-TebapivatTime frame: Up to Day 21
- T1/2 in Plasma and Whole Blood for Total RadioactivityTime frame: Up to Day 42
- Ratio of AUC0-inf for Tebapivat to AUC0-inf for Total Radioactivity in PlasmaTime frame: Up to Day 42
- Ratio of AUC0-inf for Total Radioactivity in Whole Blood to AUC0-inf for Total Radioactivity in PlasmaTime frame: Up to Day 42
- Total Clearance Following IV Administration (CL) of [13C2,15N3]-TebapivatTime frame: Up to Day 21
- Apparent Volume of Distribution During the Terminal Phase Following IV Administration (Vz) of [13C2,15N3]-TebapivatTime frame: Up to Day 21
- Apparent Volume of Distribution at Steady State Following IV Administration (Vss) of [13C2,15N3]-TebapivatTime frame: Up to Day 21
- Ratio of Dose-Normalized AUC0-inf of Oral Administration of [14C]-Tebapivat Relative to IV Administration of [13C2,15N3]-TebapivatTime frame: Up to Day 21
- Quantitation of Major Metabolites of [14C]-Tebapivat in Plasma After Oral AdministrationTime frame: Up to Day 21
- Quantitation of Major Metabolites of [14C]-Tebapivat in Excreta After Oral AdministrationTime frame: Up to Day 42
- Identification of Chemical Structure of Major Metabolites of [14C]-Tebapivat in Plasma After Oral AdministrationTime frame: Up to Day 21
- Identification of Chemical Structure of Major Metabolites of [14C]-Tebapivat in Excreta After Oral AdministrationTime frame: Up to Day 42
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Taha El-Shahat
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.